

Thursday March 30, 2023



## 2022 Annual Results Earnings Call

### Dear Investors:

Hua Medicine (2552.HK) cordially invites you or your representative to attend the conference call for the Company's 2022 annual results, which will be held 9:00 AM HKT, March 30, 2023 (Thursday).

During the conference call, management will provide a review of the Company's annual financial results in 2022, business updates, as well as address plans for the future.

### Details of the earnings call are as follows:

<b>Date:</b>	March 30,2023
<b>Time:</b>	Login starts: 8:45AM HKT Meeting starts: 9:00AM HKT
<b>Duration:</b>	Approximately 1h (including Q&A session)
<b>Language:</b>	English
<b>Management:</b>	Dr. Li Chen, Founder and CEO Mr. George Lin, EVP and Chief Financial Officer
<b>Moderator:</b>	Mr. Ziyi Chen, China Healthcare Analyst, Goldman Sachs
<b>RSVP:</b>	Join zoom webinar: <a href="#">Hua Medicine Earnings Call</a>  *Please register via the link above *No replay is available *Kindly provide the phone number which you will use for joining in advance for identification

### About Hua Medicine

Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute to global innovation in diabetes care. Hua Medicine's HuaTangNing (华堂宁®) (dorzagliatin tablets) targets the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients. It was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone, monotherapy, or in combination with metformin hydrochloride-tolerated T2D patients. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. Hua Medicine has partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing (华堂宁®) in China, benefiting diabetic patients and their families. HuaTangNing (华堂宁®) has also demonstrated its potential of achieving diabetes remission in clinical studies to help millions of diabetic patients around the world.